# The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement

Study · id `cardio:ct-nct04573049` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04573049](<https://clinicaltrials.gov/study/NCT04573049>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04573049

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 124 participants.

## Technical summary

Registry record NCT04573049. Randomized; quadruple masking; primary purpose prevention. Start 2020-09-01 (actual); primary completion 2022-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 124 participants (planned count; ClinicalTrials.gov record NCT04573049, source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)
- Started: 2020-09-01 (actual) (ClinicalTrials.gov record NCT04573049, source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)
- Primary completion: 2022-04-01 (anticipated) (ClinicalTrials.gov record NCT04573049, source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04573049, source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04573049, source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04573049-2020-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
- Condition: Aortic Valve Stenosis
- Condition: Heart Failure
- Condition: Inotropic Agents
- Condition: Safety Issues
- Condition: Effect of Drug
- Condition: Cardiac Event
- Condition: Transcatheter Aortic Valve Replacement
- Intervention (Drug): Levosimendan
- Intervention (Other): Placebo
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV
- Collaborator: China International Medical Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 80a108fb4736644a9d0f26ba79e16936f573b0b988e96c3f27b1edf17b1e63b7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
